MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Following FDA review and comments, MIRA submitted its Ketamir-2 Phase 2a CIPN protocol for IRB review at a leading cancer research institution.